» Articles » PMID: 24211739

MicroRNA-101 Inhibits Human Hepatocellular Carcinoma Progression Through EZH2 Downregulation and Increased Cytostatic Drug Sensitivity

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2013 Nov 12
PMID 24211739
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Oncogene polycomb group protein enhancer of zeste homolog 2 (EZH2) has been proposed to be a target gene of putative tumor suppressor microRNA-101 (miR-101). The aim of our study was to investigate the functional role of both miR-101 and EZH2 in human hepatocellular carcinoma (HCC).

Methods: MiR-101 and EZH2 expressions were evaluated in tumor tissues of 99 HCC patients and 7 liver cancer cell lines by real-time PCR. Luciferase reporter assay was employed to validate whether EZH2 represents a target gene of miR-101. The effect of miR-101 on HCC growth as well as programmed cell death was studied in vitro and in vivo.

Results: MiR-101 expression was significantly downregulated in most of HCC tissues and all cell lines, whereas EZH2 was significantly overexpressed in most of HCC tissues and all cell lines. There was a negative correlation between expression levels of miR-101 and EZH2. Luciferase assay results confirmed EZH2 as a direct target gene of miR-101, which negatively regulates EZH2 expression in HCC. Ectopic overexpression of miR-101 dramatically repressed proliferation, invasion, colony formation as well as cell cycle progression in vitro and suppressed tumorigenicity in vivo. Furthermore, miR-101 inhibited autophagy and synergized with either doxorubicin or fluorouracil to induce apoptosis in tumor cells.

Conclusion: Tumor suppressor miR-101 represses HCC progression through directly targeting EZH2 oncogene and sensitizes liver cancer cells to chemotherapeutic treatment. Our findings provide significant insights into molecular mechanisms of hepatocarcinogenesis and may have clinical relevance for the development of novel targeted therapies for HCC.

Citing Articles

Aberrant activation of a miR-101-UBE2D1 axis contributes to the advanced progression and chemotherapy sensitivity in human hepatocellular carcinoma.

Mu X, Wei Y, Fan X, Zhang R, Xi W, Zheng G Cell Death Discov. 2024; 10(1):422.

PMID: 39353886 PMC: 11445525. DOI: 10.1038/s41420-024-02193-y.


Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.

Liu B, Liu L, Liu Y Front Immunol. 2024; 15:1450487.

PMID: 39315094 PMC: 11416969. DOI: 10.3389/fimmu.2024.1450487.


Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies.

Walweel N, Aydin O ACS Omega. 2024; 9(26):27832-27852.

PMID: 38973850 PMC: 11223161. DOI: 10.1021/acsomega.4c02234.


EMCMDA: predicting miRNA-disease associations via efficient matrix completion.

Qin C, Zhang J, Ma L Sci Rep. 2024; 14(1):12761.

PMID: 38834687 PMC: 11150514. DOI: 10.1038/s41598-024-63582-y.


Cucurbit[8]uril-based supramolecular theranostics.

Wu D, Wang J, Du X, Cao Y, Ping K, Liu D J Nanobiotechnology. 2024; 22(1):235.

PMID: 38725031 PMC: 11084038. DOI: 10.1186/s12951-024-02349-z.